Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Report: Biotech M & A Activity on the Rise

By Pharmaceutical Processing | February 24, 2011

According to Deal Search Online, an Irving Levin Associates M&A
database $57.5 billion was committed to biotechnology M&A in 2010, a 21%
increase from last year despite there being 78 fewer reported deals compared to
2009. This is the second highest amount of money committed to the biotechnology
sector over the past decade; in 2008, nearly $94 billion was committed. The
biotechnology industry posted a total of 115 M&A deals in 2010, a 40%
decrease from 2009’s decade high 193 deals. However, the average price per deal
has risen indicating that buyers are more confident in committing more capital
to deal making.

The five largest biotechnology M&A transactions reported
in 2010 are listed below.

1. Sanofi-Aventis SA acquired Genzyme Corp. for $18.5
billion

2. Astellas Pharma, Inc. acquired OSI Pharmaceuticals,
Inc. for $4,000,000,000

3. Grifols, SA acquired Talecris Biotherapeutics Holdings
Corp. for $4,000,000,000

4. Celgene Corp acquired Abraxis BioScience, Inc. for
$2,900,000,000

5. Johnson & Johnson Inc. acquired Crucell NV
for $ 2,290,000,000

The Sanofi-Aventis SA takeover of Genzyme Corp. for $18.5
billion announced in the third quarter of 2010 alone was larger than the
M&A totals in 2002, 2003, and 2004. This mega deal was also the second
largest takeover of the past decade, behind Roche Holding AG’s $46.8 billion
acquisition of the remaining interest in Greentech in 2008.

Over the past decade there have been a total of 1,234
reported biotech M&A deals, which generated a total of $347.5 billion in
transactions in the ten-year period ended December 31, 2010, according to data
provided by Deal Search Online, an Irving Levin Associates M&A database.
The number of deals reported and the amount of dollars committed to the
biotechnology M&A market has gradually increased over the last decade. The
increase in deal and dollar volume over the past few years has been driven by
big pharmaceutical companies which are in search of new blockbuster drugs to
replace existing drugs and their revenue, when they go off patent over the
coming years.

 

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE